Verified employee & interview reviews

Dr. Reddy's Reviews

Hyderabad, Telangana

4.7/ 5

3 reviews

Dr. Reddy's Laboratories Limited is a leading Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1984 by scientist and philanthropist Dr. Kallam Anji Reddy, the company has grown from a supplier of active pharmaceutical ingredients (APIs) into an integrated global pharmaceutical powerhouse with a presence in over 70 countries. Dr. Reddy's is dedicated to providing affordable and innovative medicines under its core corporate philosophy that "good health can't wait." The company's diversified operations are divided across several core business segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment focuses on manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, including branded and unbranded generics as well as biosimilars. This segment spans key therapeutic areas such as oncology, gastroenterology, cardiovascular, neuroscience, dermatology, and immunology. The PSAI segment encompasses the development, manufacturing, and marketing of active pharmaceutical ingredients and intermediates, serving as a critical partner to other pharmaceutical innovators globally while providing contract research and manufacturing services. Dr. Reddy's operates a robust international manufacturing and research infrastructure, featuring multiple facilities approved by rigorous international regulatory bodies like the US Food and Drug Administration (USFDA). Its prominent R&D initiatives focus heavily on complex generics, biosimilars, and differentiated formulations. The company historically achieved significant milestones, becoming the first Asian pharmaceutical company outside Japan to list on the New York Stock Exchange (NYSE: RDY) in 2001 and the first Indian pharma entity to secure a 180-day marketing exclusivity from the USFDA. Financially and strategically, Dr. Reddy's continues to scale its operations across highly regulated economies, particularly in North America and Europe, alongside strong emerging market footprints in India, Russia, and South America. For the fiscal year ending March 31, 2024, the company reported global revenues of approximately INR 28,011 crore. Under its modern leadership team, which includes Chairman K. Satish Reddy, Co-Chairman and Managing Director G.V. Prasad, and CEO Erez Israeli, Dr. Reddy's employs more than 26,000 professionals globally. The company heavily prioritizes sustainability and ESG compliance, becoming the first Indian pharmaceutical company to join the Dow Jones Sustainability World Index in 2023. Through strategic partnerships, digital transformation, and biologics, Dr. Reddy’s continuously aims to accelerate access to affordable healthcare worldwide.